Company news

BioMarin Pharmaceutical Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BioMarin to Participate in Two Virtual Investor Conferences in January

January 3, 2022

BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases

December 15, 2021

BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of Directors

December 14, 2021

BioMarin to Hold Virtual R&D Day at 11: 00am ET Today

November 29, 2021

BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates

November 18, 2021

BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates

October 26, 2021

BioMarin to Participate in Four Upcoming Virtual Investor Conferences

October 24, 2021

BioMarin to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, October 27 at 4: 30pm ET

October 11, 2021

BioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical Operations

October 3, 2021

U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings

September 5, 2021

European Commission Approves BioMarin's VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close

August 26, 2021

European Commission Approves BioMarin’s VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close

August 26, 2021

BioMarin to Participate in Three Upcoming Virtual Investor Conferences

August 24, 2021

BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates

July 27, 2021

BioMarin Announces Oral Presentation at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress with 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec in Adults with Severe Hemophilia A, Demon...

July 20, 2021

BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Con...

July 18, 2021

European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A

July 14, 2021

BioMarin to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, July 28 at 4: 30pm ET

July 13, 2021

BioMarin Announces 12 Presentations at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress

July 1, 2021

BioMarin Resubmits Marketing Authorization Application (MAA) to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A

June 27, 2021

BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close

June 24, 2021

BioMarin to Participate in the Virtual BofA Securities 2021 Napa Biopharma Conference

June 14, 2021

European Medicines Agency Grants BioMarin's Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A

May 23, 2021

BioMarin Provides Highlights of 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A

May 18, 2021

BioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting

May 11, 2021

BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates

April 28, 2021

BioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and Potential Treatment Choice

April 14, 2021

BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4: 30pm ET

April 12, 2021

BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide

March 19, 2021

BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A

March 7, 2021

BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

March 2, 2021

BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results and Corporate Updates

February 24, 2021

BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors

February 17, 2021

BioMarin Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index

January 27, 2021

BioMarin to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25 at 4: 30pm ET

January 25, 2021

BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set

January 9, 2021

BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study

December 20, 2020

BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence

November 16, 2020

BioMarin Expands Vosoritide Clinical Program

November 8, 2020

BioMarin Announces Third Quarter 2020 Total Revenues of $477 Million

November 4, 2020

BioMarin to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on November 10 at 12: 30pm ET

November 3, 2020

Food and Drug Administration Accepts BioMarin's New Drug Application for Vosoritide to Treat Children with Achondroplasia

November 1, 2020

BioMarin to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5 at 4: 30pm ET

October 21, 2020

BioMarin, Pioneer in Rare Disease Treatments for Phenylketonuria (PKU), Receives FDA Approval of Label Expansion to Allow Maximum Dose of 60 mg for Palynziq® (pegvaliase-pqpz) Injection for Treatment of Adults with PKU

October 6, 2020

Scientific Luminary and MacArthur Fellowship Winner, Kevin Eggan, Ph.D., Joins BioMarin as Head of Research and Early Development

October 4, 2020

BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307

October 1, 2020

BioMarin to Participate in Upcoming Virtual Investor Conference

September 28, 2020

BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Doses First Participant in Global PHEARLESS Phase 1/2 Study of BMN 307 Gene Therapy

September 23, 2020

BioMarin Announces Presentation of Vosoritide Phase 3 Data in Children with Achondroplasia at the American Society for Bone and Mineral Research 2020 Annual Meeting

September 10, 2020

BioMarin Announces The Lancet Publishes Detailed Vosoritide Phase 3 Data Demonstrating Statistically Significant Increase in Annualized Growth Velocity (AGV) Over 52 Weeks in Children with Achondroplasia

September 7, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 56 decks. Every deck is listed under its year.